IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
IDEAYA Biosciences announced participation in three November 2026 investor events: the UBS Global Biopharma Conference and its own Investor R&D Day on November 16, and the Jefferies Global Healthcare Conference on November 17, all in London. The R&D Day will cover Phase 1 data for IDE892, an MTA-cooperative PRMT5 inhibitor, plus RAS program progress and preclinical support for MTAP/CDKN2A and RAS-driven combination strategies, with target 2027 clinical data milestones and a CDKN2A IND targeted for H1 2027.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.